Cáncer de mama en varones: reporte de 33 casos. Análisis retrospectivo en el Instituto Nacional de Enfermedades Neoplásicas durante los años 2000-2009.

Saved in:

Bibliographic Details
Title:	Cáncer de mama en varones: reporte de 33 casos. Análisis retrospectivo en el Instituto Nacional de Enfermedades Neoplásicas durante los años 2000-2009.
Alternate Title:	Male breast cancer: report of 33 cases. Retrospective analysis at the National Institute of Neoplastic Diseases in the years 2000-2009.
Authors:	Fuentes, Hugo¹ fuenteshugo1@gmail.com, Abugattas, Julio², Cotrina, José², Gómez, Henry¹
Source:	Carcinos. mar2016, Vol. 6 Issue 1, p22-30. 9p.
Abstract (English):	Background: The aim of this study was to determine the demographic and pathological characteristics of male patients with breast cancer. Methods: We reviewed clinical records of male patients diagnosed with breast cancer from 2000 to 2009 at the Instituto Nacional de Enfermedades Neoplasicas (INEN). Data from the main clinicopathological and demographic variables, date of diagnosis, last follow-up or death were included. Survival was determined by the Kaplan- Meier method and patients were stratified according to the evaluated variables. Results: Median age was 65.3 years (range 23-87 years). Three were clinical stage (CS) I (9.1%), 13 were CS II (39.3%), and 17 were CS III-IV (51.6%). Radical mastectomy was done in 23 patients (69.7%). Of the total, 32 were ductal carcinomas (97%), whereas, only 1 case was ductal carcinoma in situ; 17 were ER/PR positive (51.5%),3 were ER positive/PR negative (9.37%), 3 were ER/RP/ cerb-B2 negative (9.1%) and 1 case was ER/RP negative cerb-B2 positive (3%). Sixteen were lymph node positive (66.7%). Regarding treatment, 10 patients received adriamycin based adjuvant chemotherapy and 4 patients had neoadjuvant treatment with anthracyclines with sequential taxanes, 17 patients (51.5%) were treated with hormonotherapy and 12 with radiotherapy. The most common site of recurrence was bone and lungs. The overall survival at 5 years was estimated in 72.5%. Conclusion: Despite having a higher percentage of cases diagnosed in advanced stages (III and IV), overall survival at 5 years was 72.5%, that because most of the patients were positive for hormone receptors. [ABSTRACT FROM AUTHOR]
Abstract (Spanish):	Introducción: El objetivo de este estudio fue conocer las características demográficas y patológicas de pacientes varones con cáncer de mama. Métodos: Se revisaron las historias clínicas del Instituto Nacional de Enfermedad Neoplásicas (INEN) de los varones diagnosticados con cáncer de mama, con confirmación patológica entre Enero del 2000 y Diciembre del 2009. Se evaluaron las variables clínico-patológicas y demográficas, fechas de diagnóstico, último contacto o fecha de fallecimiento. El cálculo de la sobrevida se realizó por el método de Kaplan-Meier y se estratificaron los pacientes de acuerdo a las variables evaluadas. Resultados: Se encontraron 33 casos elegibles para este estudio. La mediana de edad fue de 65,3 años (rango 23-87 años). Tres casos en estadio clínico (EC) I (9,1%), 13 (39,3%) en EC II y 17 (51,6%) en EC III - IV. Se realizó mastectomía radical en 23 pacientes (69,7%). Del total, 32 fueron carcinomas ductales (97%), mientras que sólo 1 caso fue carcinoma ductal in situ; 17 fueron RE/RP positivo (51,5%), 3 fueron RE positivo/RP negativo (9,37%), 3 fueron ER/PR/HER2 negativo (9,1%) y 1 fue RE-RP negativo/HER2 positivo (3%). Dieciséis tuvieron ganglios linfáticos positivos (66,7%). Respecto al tratamiento, 10 pacientes recibieron quimioterapia adyuvante a base de adriamicina y 4 pacientes recibieron tratamiento neoadyuvante con antraciclinas y taxanos secuenciales; se administró hormonoterapia en 17 pacientes (51,5%) y radioterapia en 12 pacientes. Los sitios más comunes de recidiva fueron huesos y pulmones. La sobrevida global a los 5 años se estimó en 72,5%. Conclusión: A pesar de tener un mayor porcentaje de casos en estadios clínicos avanzados (III y IV), la sobrevida global a los 5 años fue de 72,5%, esto debido a que la mayoría de los pacientes fueron positivos para receptores hormonales. [ABSTRACT FROM AUTHOR]
	Copyright of Carcinos is the property of Oncosalud S.A.C. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	MedicLatina

Description
Abstract:	Background: The aim of this study was to determine the demographic and pathological characteristics of male patients with breast cancer. Methods: We reviewed clinical records of male patients diagnosed with breast cancer from 2000 to 2009 at the Instituto Nacional de Enfermedades Neoplasicas (INEN). Data from the main clinicopathological and demographic variables, date of diagnosis, last follow-up or death were included. Survival was determined by the Kaplan- Meier method and patients were stratified according to the evaluated variables. Results: Median age was 65.3 years (range 23-87 years). Three were clinical stage (CS) I (9.1%), 13 were CS II (39.3%), and 17 were CS III-IV (51.6%). Radical mastectomy was done in 23 patients (69.7%). Of the total, 32 were ductal carcinomas (97%), whereas, only 1 case was ductal carcinoma in situ; 17 were ER/PR positive (51.5%),3 were ER positive/PR negative (9.37%), 3 were ER/RP/ cerb-B2 negative (9.1%) and 1 case was ER/RP negative cerb-B2 positive (3%). Sixteen were lymph node positive (66.7%). Regarding treatment, 10 patients received adriamycin based adjuvant chemotherapy and 4 patients had neoadjuvant treatment with anthracyclines with sequential taxanes, 17 patients (51.5%) were treated with hormonotherapy and 12 with radiotherapy. The most common site of recurrence was bone and lungs. The overall survival at 5 years was estimated in 72.5%. Conclusion: Despite having a higher percentage of cases diagnosed in advanced stages (III and IV), overall survival at 5 years was 72.5%, that because most of the patients were positive for hormone receptors. [ABSTRACT FROM AUTHOR]
ISSN:	22225730